The antibacterial activity of rufloxacin was confirmed against a large number of respiratory and urinary tract pathogens collected in five European countries. In terms of both MIC» values and percentages of susceptible isolates found, this new quinolone showed useful in-vitro activity against Mycoplasma catarrhalis, Haemophilus influenzae and Klebsiella pneumoniae, with a large proportion of Staphylococcus aureus also covered, while, as expected Streptococcus pneumoniae and Streptococcus pyogenes were not included in its antibacterial spectrum. Rufloxacin was comparable with the other antibiotics against these pathogens with the exception of streptococci. Against these microorganisms, /Mactams were the most active agents. Against the urinary pathogens the in-vitro activity of rufloxacin is similar to that of norfloxacin although this latter drug is more active in terms of MIC» values and in percentages of strains inhibited. In many cases more isolates were susceptible to the remaining comparator agents than to rufloxacin. However, there were no significant differences between the numbers of microorganisms inhibited by the various drugs and rufloxacin. The findings of this survey do not seem to modify the general picture which emerged in previous studies and further confirms its useful spectrum in different geographic settings.
Introduction
Rufloxacin (MF-934) is a new oral fluoroquinolone with an in-vitro potency similar to that displayed by norfloxacin (Ravizzola et al., 1989; Mattina et al., 1991; Wise et al., 1992) . Its antibacterial spectrum encompasses all Enterobacteriaceae, with the exception of Klebsiella, Serralia and Enterobacter spp. Haemophilus influenzae, Mora.xella catarrhalis and methicillin-sensitive staphylococci, as well as some intracellular microorganisms, such as chlamydia, and Legionella pneumophila; Mycoplasma are also included with Streptococcus pneumoniae being marginally susceptible (Ravizzola et al., 1989; Mattina et al., 1991; Wise et al., 1992; Furneri et al., \994a,b) .
This new quinolone is characterised by a long half-life (30-35 h), reaches high concentrations in biological fluids, and penetrates well into tissues (Boerema et al., 1991a; Wise et al., 1991; Cogo et al., 1992; Kisicki et al., 1992; Wise et al., 1993) . The peak blood levels after a single dose of 400 mg or at the steady-state after multiple 200 mg daily doses range between 3 and 5 mg/L. High concentrations (around 40-50 mg/L) of rufloxacin are maintained in urine for at least 3 days (Aguilar et al., 1996) . These favourable pharmacokinetic characteristics may contribute to the therapeutic efficacy of rufloxacin. Previous studies have shown in fact a high percentage of bacteriological eradications and clinical cure rates (Boroema et al., 19916; Dirksen, Focht& Boerema, 1991; Klietmann etal., 1993; Bach et al., 1995; Jardin et al., 1995) .
On the basis of a half-life of 30 h, a C mtx of 4 mg/L, a protein binding of 60% and MICs < 4 mg/L for strains that have successfully been eradicated from urinary and respiratory tract infections, the European Study Group for Antibiotic Breakpoint Determination of the European Society for Clinical Microbiology and Infectious Diseases has tentatively assigned to rufloxacin breakpoint values of <.2,4 and ;>8 mg/L for susceptibility, intermediate susceptibility and resistance, respectively (Phillips et al., 1993) .
It is thus possible to assess the in-vitro susceptibility of respiratory and urinary clinical strains to rufloxacin and other suitable comparator agents in Italy, France, Spain, Germany and the United Kingdom where rufloxacin is planned to be introduced.
Materials and methods

Study design
The study was conducted from October 1993 to May 1994, in In addition to rufloxacin, respiratory strains were assayed against amoxycillin, amoxycillin-clavulanate co-amoxiclav cefixime, ciprofloxacin and clarithromycin. The in-vitro activity of trimethoprim-sulphamethoxazole (co-trimoxazole), cefixime, norfloxacin and gentamicin against the collection of urinary pathogens was also assessed. Rufloxacin was supplied to each centre in the form of pure powder (2 g), batch no. 080714, by Mediolanum Farmaceutici (Milan, Italy). The individual participating laboratories were responsible for the other comparative compounds used.
Susceptibility testing
Minimum inhibitory concentrations (MICs) were determined for all agents employing a standard agar-dilution technique based on the National Committee for Clinical Laboratory Standards (NCCLS, 1993) . A single batch of Mueller-Hinton (Oxoid, Basingstoke, UK) agar was provided to all participating centres by Mediolanum Farmaceutici. Optimal growth of respiratory pathogens was assured by supplementing the basal medium with 5% saponin-lysed horse blood and 10 mg/L nicotinamide adenine dinucleotide (for H. influenzae). Lysed blood (5%) was also added to all tests evaluating the in-vitro activity of co-trimoxazole.
Organisms were inoculated from overnight cultures in nutrient broth (Enterobacteriaceae) or Brain Heart Infusion broth (staphylococci), diluted to produce an inoculum of approximately 10 4 bacteria. Moraxella, streptococci and Haemophilus were grown on supplemented solid media with suspensions being made in nutrient broth followed by a dilution step to provide the same inoculum as described above. Except for Haemophilus, which was kept under microaerophilic conditions of 5% CO 2 , inoculated plates were incubated overnight at 37°C in air for all microorganisms. The MICs were defined as the lowest concentration of antibiotic at which no visible growth, or less than five individual colonies, were seen.
The MIC interpretative breakpoints for rufloxacin were those previously published (Phillips et al., 1993) , while for the other antimicrobial agents they were those recommended by NCCLS (1993) .
Quality control
The MICs of the following five reference strains provided by the Coordinating Centre to the other participating units were determined: H. influenzae, S. pneumonias, E. coli, S. aureus, and P. aeruginosa. However, one centre (Munich) used H. influenzae ATCC 33533 and P. aeruginosa ATCC, and another (London) also studied S. aureus NCTC 6571 and E. coli NCTC 10418 27853 as quality control test strains.
Susceptibility data from each centre were considered to be acceptable when the MIC for the reference strains was within one doubling dilution of the expected range values provided by the Coordinating Centre or, for the ATCC strains, if they were within the limits established by NCCLS (1993) .
Results
The results obtained with the reference strains were considered acceptable, since the overall laboratory mode MIC for each control strain and for each antibiotic tested was ± 1 doubling dilution within the expected variation range in 100% of the cases (Table I) .
A total of 2367 clinical isolates (1160 respiratory and 1207 urinary tract pathogens) were studied.
Data on the susceptibility of respiratory species to rufloxacin and comparative drugs are reported in •Range provided by the Co-ordinating Centre. 
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'Breakpoints for these drugs against S. pneumoniae not available (n.a.) in the NCCLS (1993) guidelines.
> K. pneumoniae (MIG» values of 0.5, 2 and 8 mg/L, respectively). The MIG»s for the Gram-positives were ^ 16 mg/L. The in-vitro potency of rufloxacin was also confirmed by the percentages of susceptible strains. At the breakpoint of < 2 mg/L rufloxacin inhibited 98.7% H. influenzae, 98.3% M. catarrhalis, 87.5% K. pneumoniae and 74.4% S. aureus. However, only 5% of S. pyogenes were susceptible.
Among the comparator drugs, amoxycillin, as expected, was less active than co-amoxiclav against respiratory pathogens. The difference in the incidence of susceptible strains was marked not only for M. catarrhalis (from 24.7% to 100%) and K. pneumoniae (from 1.8% to 85.7%), but also for H. influenzae (from 71.8% to 96.6%), and S. aureus (from 23.2% to 83.2%). 5. pyogenes was found to be fully susceptible (100%) to both drugs. The antibacterial spectrum of rufloxacin was confirmed against the urinary pathogens (Table III) . In terms of MICM values, all the isolates examined were covered by the drug with the exception of P. aeruginosa and Providencia stuartii. With respect to the percentage of strains inhibited, rufloxacin was active against from 53.7% {Serratia marcescens) to 94.7% (Citrobacter diversus) of the isolates.
Considering the comparator antibiotics, norfloxacin inhibited uropathogens in a range from 66.9% (P. aeruginosa) to 100% (C. diversus). The percentage of co-trimoxazole-susceptible strains ranged from 43.9% (S. marcescens) to 84.2% (C. diversus). Cefixime inhibited over 90% of the E. coli, Proteus spp., K. pneumoniae and C. diversus strains. Gentamicin was active against all the species tested with from 72.3% {P. aeruginosa) to 100% of the strains being inhibited.
Susceptibility results by country are given in Table IV . Rufloxacin was found to be a potent agent against M. catarrhalis (>92%) and H. influenzae (>94%) in all sites. K. pneumoniae susceptible isolates ranging from 63.6% in France, 80% in Spain, to >90% in the others. S. pyogenes was totally resistant to this quinolone in France, while a range of susceptilibity from 1.9% (UK) to 17.5% (Italy) was observed in other countries. Forty-seven per cent of S. aureus were inhibited in France, 61.5% in Spain, while 80%, 83% and 90% of the isolates were susceptable in Italy, the UK and Germany, respectively.
Co-amoxiclav was inhibitory against all pathogens in all countries with the exception of S. aureus. The susceptibility of the strains were 93.3% of the German and 85% of the Italian strains. 63.1% of the French and 65.3% of the Spanish.
Cefixime inhibited 100% M. catarrhalis, H. influenzae and S. pyogenes strains, with only a few (2%) resistant isolates of the latter being found in Italy and France. Similarly, cefixime was totally active against K. pneumoniae in Germany, Italy, Spain and the UK, but only 63.6% of the strains were inhibited by this compound in France.
With the exception of the UK, where two strains of ciprofloxacin-resistant H. influenzae were found, ciprofloxacin inhibited all M. catarrhalis and H. influenzae isolates in all the countries. A 37% resistance rate of K. pneumoniae was found in France, as compared to other countries (0%). Inhibition varied for S. aureus (from 47.3% in France and 65.3% in Spain, respectively, to 85% and 93% in Italy, UK and Germany).
Clarithromycin was highly active against M. catarrhalis strains (>96% of strains susceptible) in all countires. With H. influenzae, the highest proportion of susceptible isolates was recorded in Germany (81.3%), while in other nations the values ranged from 52.5% (Italy) to 66% (France). 5. pyogenes had a high percentage of inhibited strains (from 90% and 98% in Italy and France to 100% in other countries). Clarithromycin was active against 80%, 76.6% and 75% of S. aureus in Germany, the With representative urinary pathogens (Table V) , a high percentage of E. coli was found to be susceptible to rufloxacin in the UK, (98.3%), Germany (95%) and France (83.7%). Italy and particularly Spain reported a somewhat lower percentage (69.7% and 54.8%). We obtained similar results for norfloxacin (see below), thus reflecting recently reported data on the spread of fluroquinolone-resistant E. coli isolated in Spain from patients with urinary tract infections (21,22). K. pneumoniae was highly susceptible to rufloxacin in Germany (89.6%) and the UK (87.5%), while a lower percentage of susceptibility was recorded in Italy (75%), France (70.6%) and Spain (61.1%). With reference to M. morganii, 81.3% of the isolates were inhibited by rufloxacin in France, 89.5% and 90.9% in the UK and Italy respectively, 95.8% in Germany and 100% in Spain. P. vulgaris was found fully susceptible to this quinolone in Germany and Spain. The percentages of susceptible organisms were 92.9% in France, 88.9% in the UK and 81.3% in Italy. P. mirabilis isolates were highly susceptible to rufloxacin both in Germany (95%) and in the UK (93.3%), whereas they were less susceptible in Spain and Italy (66.7%) and especially in France (31.6%). With a few exceptions in the UK and Germany (10% and 7% susceptibility rates, respectively), rufloxacin-susceptible P. aeruginosa were not found, as expected. Susceptibility rates of 5. saprophyticus varied between countries from a high 80% and 70% (Italy and Germany) to a lower 57.1 % (UK), down to 40% and 20% (Spain and France, where only few isolates were tested).
Norfloxacin was effective against a large number of urinary pathogens in Germany and the UK, with susceptibility rates exceeding 70% for E. coli, S. saprophyticus, and P. aeruginosa. Urinary species were generally susceptible to norfloxacin in France (from 87.5% to 100%), with the exception of P. aeruginosa (57.1%), and S. saprophyticus () Number of strains tested; F, France; D, Germany; I, Italy; E, Spain; UK, United Kingdom. Breakpoint for susceptibility (in mg/L): rufloxacin s4; amoxycillin ^4; co-amoxidav ^4; cefixime i I; ciprofloxacin <, I; clarithromycin <,2. In Germany, more than 80% of the species were inhibited by gentamicin. In the UK, there were more than 87.5% gentamicin-susceptible strains, with the exception of S. saprophyticus (78.6%). A wide range of species were also inhibited by gentamicin in Spain (80%-100%), with the exception of P. aeruginosa (72.7%). A low percentage of susceptibility was found in Italy and in France against P. aeruginosa (26.3% and 61.9%, respectively), while other common urinary species were > 80% susceptible. Only 20% of S. saprophyticus strains were susceptible to gentamicin in France.
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Discussion
The antibacterial activity of rufloxacin, as depicted in previous studies (Ravizzola et al., 1989; Mattina et al., 1991; Wise et al., 1992) , was confirmed on a larger number of respiratory and urinary tract pathogens collected in five European countries.
The sensitivity of clinical isolates to rufloxacin and other comparator antibiotics in our study varied between countries and was slightly lower than expected (Ravizzola et al., 1989; Mattina et al., 1991; Wise et al., 1992) . This could be due to the fact that almost two thirds of the isolates were collected from hospitalised patients with difficult-to-treat infections. The inclusion of clusters of resistant strains could therefore have occurred. An increased level of fluoroquinolone-resistance in European isolates, especially those from France, Italy and Spain cannot be excluded (Aguilar et al., 1992; Perez-Trailer et al., 1993) . This is in fact suggested by the results of this survey, where rufloxacin-, norfloxacin-and ciprofloxacin-resistance levels for individual species were consistently higher in Southern than in North-western (UK) and Central Europe (Germany). Similar findings have been recently published by others (Kresken et al., 1994) .
In terms of MIQo values, MIC mode values and percentages of susceptible isolates, rufloxacin showed a useful in-vitro activity against M. catarrhalis, H. influenzae and K. pneumoniae, with a large proportion of S 1 . aureus also being covered. As expected, 5. pneumoniae and S. pyogenes were not included in its antibacterial spectrum (MIG» values of ;>16mg/L).
Rufloxacin favourably compared with the other antibiotics against respiratory pathogens with the exception of streptococci, against which /Mactam drugs were confirmed to be the most active compounds. Although non-quinolone comparative agents occasionally were shown to be more potent than rufloxacin, differences were not striking. As far as the comparison with fluoroquinolone-antimicrobials is concerned and in terms of percentage of susceptible isolates, the activity of rufloxacin equalled the activity of ciprofloxacin against all respiratory species tested, with the exception of 5. pneumoniae and S. pyogenes which were less susceptible. Major differences between rufloxacin and ciprofloxacin were found when the activity was expressed in terms of MIC50 and MICV Interestingly, it should be underlined that the two H. influenzae strains with resistance to ciprofloxacin also had raised MICs to rufloxacin.
The in-vitro activity of rufloxacin against urinary pathogens was generally similar to that of norfloxacin. Nevertheless, norfloxacin exhibited slightly greater activity (approximately 10%) in terms of percentages of strains inhibited. However, norfloxacin breakpoints are internationally established for urinary tract infections (based on the fact that the drug concentrates in urine), whereas the breakpoints for rufloxacin are still tentative and those that have been proposed both for urinary and respiratory infections, take into account only the concentration of the drug in plasma. It can therefore be argued that the suggested rufloxacin breakpoints need to be reassessed and possibly modified for urinary indications, considering the high and sustained levels that are reached in urine by the drug. The proportion of urinary isolates found to be fully susceptible to rufloxacin may therefore have been underestimated in this study. The assessment of the eradication rate for bacteria with MICs ^ 4 mg/L in patients treated with rufloxacin in UTI clinical trials will provide more precise information to establish a new breakpoint. This could be particularly important for conditions caused by organisms with borderline susceptibility (e.g. P. mirabilis and S. saprophyticus) and P. aeruginosa, which is the most common urinary pathogen with in-vitro resistance to rufloxacin (4% of strains being fully susceptible).
The results of this survey confirm the activity of rufloxacin against clinical isolates which emerged in previous studies and further confirm its useful antimicrobial spectrum against urinary and Gram-negative respiratory tract pathogens in different parts of Europe.
